Scientific EXPERT Act of 2025
S. 822
This bill requires the Food and Drug Administration (FDA) to facilitate and participate in externally led, science-focused drug development meetings to discuss the development of treatments for rare diseases and conditions.
Learn about this bill’s status and read its full summary in the Pocket Congress app.
Open in the Pocket Congress app 
Scan to open this page in Pocket Congress